A Novel Xenograft Model of Human Hepatocellular Carcinoma in Immunocompetent Mice Based on the Microcarrier-6.

Yanzhen Bi,Shanshan Li,Huixin Tang,Quanquan Wang,Quanyi Wang,Yonghong Yang,Xiaobei Zhang,Zhenfeng Shu,Zhongping Duan,Yu Chen,Feng Hong

DOI: https://doi.org/10.1016/j.trim.2022.101738

IF: 2.032

2022-01-01

Transplant Immunology

Abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is one of the most common malignant tumors that threaten human health; thus, the establishment of an animal model with clinical features similar to human hepatocellular carcinoma is of important practical significance.METHODS:Taking advantage of the novel microcarrier-6, human HCC cells were injected into immunocompetent mice to establish a novel human HCC patient-derived xenograft (PDX) model. Primary HCC cells were isolated from fresh hepatocellular carcinoma tissues, which were subsequently co-cultured with microcarrier-6 to construct a three-dimensional tumor cell culture model in vitro. The HCC-microcarrier complex was implanted into mice by subcutaneous inoculation, and the tumor formation time, tumor formation rate, and pathological manifestation were recorded. Changes of immune parameters in mice were detected by flow cytometry.RESULTS:The success rate was 60% (6/10) in the establishment of hepatocellular carcinoma PDX mouse model, and the total tumor formation rate of the tumor-forming model is 90-100%. H&E staining and immunohistochemical experiments indicate that the model well retained the characteristics of the primary tumor. Interestingly, M2 macrophages in tumor-bearing mice increased significantly, and the levels of CD4+ T cells were significantly reduced.CONCLUSIONS:Through the application of the microcarrier-6 in immunocompetent mice, we successfully established a novel human HCC PDX model, which can be used to better study and further elucidate the occurrence and pathogenic mechanism of HCC, improve the predictability of toxicity and drug sensitivity in HCC.